HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German OTC Market News: Allergy, Pain And Sleep Launches From Sanofi, Teva And P&G

Executive Summary

The latest German consumer healthcare launches: Sanofi adds bilastine antihistamine to Allegra range; Teva's Ratiopharm delivers paracetamol and ibuprofen combo thanks to Rx-to-OTC switch; and P&G livens up WICK ZzzQuil sleep aid gummies with tropical fruit flavour. 

You may also be interested in...



Blame The ‘Hamsters’: Germany’s Paediatric Fever Medicine Shortage Worsens

An ongoing crisis in the availability of children's fever medicines in Germany is due to stockpiling – or “hamstering” – by pharmacists and wholesalers, says the country's medicines regulator. This is disputed by not just pharmacists and wholesalers, but also manufacturers, which blame Germany's fixed price system for reimbursable medicines, which includes OTC children's fever medicines. Nevertheless, the German government is seeking to address the real causes of the crisis with a new draft generics law, which is being welcomed by industry. 

Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda

Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.

Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?

HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel